A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Stopped Company decision to stop trial, withdraw the IND and close down operations.

Conditions

• Cancer
• Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Interventions

• DRUG: Fludarabine (Conditional therapy)
• DRUG: Cyclophosphamide Monohydrate (Conditional therapy)
• DRUG: firi-cel (Experimental drug)

Sponsor

CARGO Therapeutics